4.6 Article

Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis

期刊

PLOS ONE
卷 9, 期 1, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0087508

关键词

-

资金

  1. European Union [259867]
  2. EU
  3. France, Agence Nationale de la Recherche (ANR)
  4. Germany, Bundesministerium fur Bildung und Forschung (BMBF)
  5. Ireland, Health Research Board (HRB)
  6. Italy, Ministero della Salute
  7. Netherlands, The Netherlands Organisation for Health Research and Development (ZonMw)
  8. Poland, Narodowe Centrum Badan i Rozwoju
  9. Portugal, Fundacao a Ciencia e a Tecnologia
  10. Spain, Ministerio de Ciencia e Innovacion
  11. Switzerland, Schweizerischer Nationalfonds zur Forderung der wissenschaftlichen Forschung (SNF)
  12. Turkey, Tubitak
  13. United Kingdom, Medical Research Council (MRC)
  14. MND Association/MRC Lady Edith Wolfson Fellowship [MR/K003771/1]
  15. MRC PhD studentship
  16. NIHR
  17. MRC [MR/K003771/1, MR/K000039/1] Funding Source: UKRI
  18. Medical Research Council [MR/K000039/1, MR/K003771/1] Funding Source: researchfish
  19. National Institute for Health Research [NF-SI-0512-10082] Funding Source: researchfish

向作者/读者索取更多资源

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes death within a mean of 2-3 years from symptom onset. There is no diagnostic test and the delay from symptom onset to diagnosis averages 12 months. The identification of prognostic and diagnostic biomarkers in ALS would facilitate earlier diagnosis and faster monitoring of treatments. Gene expression profiling (GEP) can help to identify these markers as well as therapeutic targets in neurological diseases. One source of genetic material for GEP in ALS is peripheral blood, which is routinely accessed from patients. However, a high proportion of globin mRNA in blood can mask important genetic information. A number of methods allow safe collection, storage and transport of blood as well as RNA stabilisation, including the PAXGENE and TEMPUS systems for the collection of whole blood and LEUKOLOCK which enriches for the leukocyte population. Here we compared these three systems and assess their suitability for GEP in ALS. We collected blood from 8 sporadic ALS patients and 7 controls. PAXGENE and TEMPUS RNA extracted samples additionally underwent globin depletion using GlobinClear. RNA was amplified and hybridised onto Affymetrix U133 Plus 2.0 arrays. Lists of genes differentially regulated in ALS patients and controls were created for each method using the R package PUMA, and RT-PCR validation was carried out on selected genes. TEMPUS/GlobinClear, and LEUKOLOCK produced high quality RNA with sufficient yield, and consistent array expression profiles. PAXGENE/GlobinClear yield and quality were lower. Globin depletion for PAXGENE and TEMPUS uncovered the presence of over 60% more transcripts than when samples were not depleted. TEMPUS/GlobinClear and LEUKOLOCK gene lists respectively contained 3619 and 3047 genes differentially expressed between patients and controls. Real-time PCR validation revealed similar reliability between these two methods and gene ontology analyses revealed similar pathways differentially regulated in disease compared to controls.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据